Cargando…
Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatolo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530861/ https://www.ncbi.nlm.nih.gov/pubmed/28790806 http://dx.doi.org/10.2147/PPA.S137052 |
_version_ | 1783253314047049728 |
---|---|
author | González, Carlos M Carmona, Loreto de Toro, Javier Batlle-Gualda, Enrique Torralba, Antonio I Arteaga, María J Cea-Calvo, Luis |
author_facet | González, Carlos M Carmona, Loreto de Toro, Javier Batlle-Gualda, Enrique Torralba, Antonio I Arteaga, María J Cea-Calvo, Luis |
author_sort | González, Carlos M |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatologists and three patients, including Likert questions on the impact of disease and treatment on daily life and preferred attributes of treatment. Rheumatologists from 50 participating centers were instructed to handout the survey to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home and sent it to a central facility by prepaid mail. RESULTS: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), and close relatives’ life (32.3%); 30%–50% patients reported seldom/never being inquired about these aspects by their rheumatologists. Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was high (>80% were “satisfied” or “very satisfied”), despite moderate/severe impact of disease. CONCLUSION: Patients with rheumatic diseases on SC biological therapy perceive a high disease impact on different aspects of daily life, despite being highly satisfied with their treatment; the perception is that physicians do not frequently address personal problems. Normalization of QoL is the most important attribute of therapies to patients. |
format | Online Article Text |
id | pubmed-5530861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55308612017-08-08 Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products González, Carlos M Carmona, Loreto de Toro, Javier Batlle-Gualda, Enrique Torralba, Antonio I Arteaga, María J Cea-Calvo, Luis Patient Prefer Adherence Original Research OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatologists and three patients, including Likert questions on the impact of disease and treatment on daily life and preferred attributes of treatment. Rheumatologists from 50 participating centers were instructed to handout the survey to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home and sent it to a central facility by prepaid mail. RESULTS: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), and close relatives’ life (32.3%); 30%–50% patients reported seldom/never being inquired about these aspects by their rheumatologists. Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was high (>80% were “satisfied” or “very satisfied”), despite moderate/severe impact of disease. CONCLUSION: Patients with rheumatic diseases on SC biological therapy perceive a high disease impact on different aspects of daily life, despite being highly satisfied with their treatment; the perception is that physicians do not frequently address personal problems. Normalization of QoL is the most important attribute of therapies to patients. Dove Medical Press 2017-07-19 /pmc/articles/PMC5530861/ /pubmed/28790806 http://dx.doi.org/10.2147/PPA.S137052 Text en © 2017 González et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research González, Carlos M Carmona, Loreto de Toro, Javier Batlle-Gualda, Enrique Torralba, Antonio I Arteaga, María J Cea-Calvo, Luis Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title | Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title_full | Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title_fullStr | Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title_full_unstemmed | Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title_short | Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products |
title_sort | perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: rheu-life, a survey to patients treated with subcutaneous biological products |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530861/ https://www.ncbi.nlm.nih.gov/pubmed/28790806 http://dx.doi.org/10.2147/PPA.S137052 |
work_keys_str_mv | AT gonzalezcarlosm perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT carmonaloreto perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT detorojavier perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT batllegualdaenrique perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT torralbaantonioi perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT arteagamariaj perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts AT ceacalvoluis perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts |